Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(100%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 4 finished

Non-Completion Rate

100.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(4)

Detailed Status

Terminated4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

terminated4100%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

NCT03434353
terminatedphase_2

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

NCT04023721
terminatedphase_2

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

NCT04059198
terminatedphase_2

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

NCT03932513

Clinical Trials (4)

Showing 4 of 4 trials
NCT03434353Phase 2

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Terminated
NCT04023721Phase 2

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

Terminated
NCT04059198Phase 2

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Terminated
NCT03932513Phase 2

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4